Clinical Trials Logo

Nervous System Neoplasms clinical trials

View clinical trials related to Nervous System Neoplasms.

Filter by:

NCT ID: NCT00005081 Completed - Clinical trials for Brain and Central Nervous System Tumors

Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma

Start date: August 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining carmustine and O6-benzylguanine in treating patients who have recurrent or progressive glioma.

NCT ID: NCT00004937 Completed - Clinical trials for Brain and Central Nervous System Tumors

Acridine Carboxamide in Treating Patients With Recurrent Glioblastoma Multiforme

Start date: October 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of acridine carboxamide in treating patients who have recurrent glioblastoma multiforme.

NCT ID: NCT00004892 Completed - Clinical trials for Brain and Central Nervous System Tumors

O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma

Start date: April 2000
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of O6-benzylguanine and implanted carmustine wafers in treating patients who have recurrent malignant glioma.

NCT ID: NCT00004868 Completed - Clinical trials for Brain and Central Nervous System Tumors

SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy

Start date: March 24, 2000
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: SU5416 may stop the growth of astrocytoma or glioma by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of SU5416 in treating patients who have recurrent astrocytoma or mixed glioma that has not responded to previous radiation therapy.

NCT ID: NCT00004259 Completed - Clinical trials for Brain and Central Nervous System Tumors

Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas

Start date: June 2000
Phase: Phase 3
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as temozolomide, carmustine, and lomustine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: This randomized phase III trial is studying radiation therapy and temozolomide to see how well they work compared to radiation therapy and carmustine or lomustine in treating patients with anaplastic astrocytoma or mixed gliomas.

NCT ID: NCT00004224 Completed - Clinical trials for Brain and Central Nervous System Tumors

Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma

Start date: January 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug and combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying combination chemotherapy and radiation therapy to see how well they work in treating children with localized ependymoma.

NCT ID: NCT00004212 Completed - Lymphoma Clinical Trials

DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas

Start date: September 1999
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of DX-8951f in treating children who have advanced solid tumors or lymphomas that have not responded to previous therapy.

NCT ID: NCT00004204 Active, not recruiting - Clinical trials for Brain and Central Nervous System Tumors

Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma

Start date: February 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have recurrent or progressive malignant glioma.

NCT ID: NCT00004200 Completed - Clinical trials for Brain and Central Nervous System Tumors

Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Start date: October 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Prinomastat may stop the growth of glioblastoma multiforme by stopping blood flow to the tumor. Drugs used in chemotherapy stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to study the effectiveness of prinomastat plus temozolomide in treating patients who have newly diagnosed glioblastoma multiforme.

NCT ID: NCT00004147 Completed - Clinical trials for Brain and Central Nervous System Tumors

COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors

Start date: July 2000
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: COL-3 may stop the growth of brain tumors by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of COL-3 in treating patients who have progressive or recurrent brain tumors following radiation therapy or chemotherapy.